Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 4/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.44 |
| ▸ | BCL2 | P10415 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.43 |
| ▸ | PDE6D | O43924 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | IRAK3 | Q9Y616 | 3/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24671771 | 1.00 | STAT3 (0.48) | STAT3DYRK2CRBNCA2DDB1 | |
| SCHEMBL24671633 | 0.99 | STAT3 (0.47) | STAT3DYRK2CRBNCA2DDB1 | |
| SCHEMBL23946161 | 0.93 | STAT3 (0.48) | STAT3DYRK2CRBNCA2DDB1 | |
| SCHEMBL23915711 | 0.90 | CRBN (0.47) | STAT3CRBNCA2DDB1HDAC1 | |
| SCHEMBL22511915 | 0.90 | STAT3 (0.47) | STAT3DYRK2CRBNCA2DDB1 | |
| SCHEMBL20260253 | 0.89 | CRBN (0.51) | STAT3DYRK2CRBNCA2DDB1 | |
| SCHEMBL26012658 | 0.86 | STAT3 (0.47) | STAT3DYRK2CRBNCA2DDB1 | |
| SCHEMBL22959804 | 0.86 | STAT3 (0.45) | STAT3DYRK2CRBNCA2DDB1 | |
| SCHEMBL22959685 | 0.86 | STAT3 (0.44) | STAT3DYRK2CRBNCA2DDB1 | |
| SCHEMBL26366310 | 0.85 | STAT3 (0.44) | STAT3DYRK2CRBNCA2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | HIPK1, MCL1, HYPK | STAT3 2294/4885DYRK2 424/4885CRBN 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.